ResMed CEO Michael Farrell sells $1.68 million in stock

SAN DIEGO—Michael J. Farrell, the Chief Executive Officer of ResMed Inc . (NYSE:RMD), recently sold a significant portion of his shares in the company. According to a Form 4 filing with the Securities and Exchange Commission, Farrell sold 8,009 shares of ResMed common stock on April 7, 2025, at a weighted average price of $209.85 per share, totaling approximately $1.68 million. The transaction comes as ResMed, currently valued at nearly $30 billion, shows strong financial health according to InvestingPro analysis, with a "GREAT" overall rating.

The sale was part of a pre-arranged trading plan under Rule 10b5-1, which Farrell adopted on October 31, 2024. This plan allows company insiders to sell a predetermined number of shares at a predetermined time, providing an opportunity to manage their holdings while avoiding potential insider trading violations.

In addition to the sale, Farrell also exercised stock options to acquire 8,009 shares at a price of $101.64 per share on the same day, valued at approximately $814,034. After these transactions, Farrell holds 455,472 shares directly and has additional indirect holdings through the Lisette and Michael Farrell Family Trust.

ResMed Inc., headquartered in San Diego, California, specializes in the development and manufacturing of medical devices for treating sleep apnea and other respiratory conditions. The company maintains a perfect Piotroski Score of 9, reflecting strong operational efficiency, and investors should note the upcoming earnings report scheduled for April 23, 2025. For deeper insights into ResMed's financial health and growth prospects, InvestingPro offers 12 additional exclusive tips and a comprehensive Pro Research Report.

In other recent news, ResMed reported earnings for Q2 FY2025, exceeding analyst expectations with an earnings per share (EPS) of $2.43 and revenue of $1.28 billion. This performance surpassed forecasts of $2.32 EPS and $1.27 billion in revenue, marking a 10% year-over-year increase in group revenue. Despite these strong results, the stock experienced a decline in after-hours trading. Additionally, ResMed has been added to Goldman Sachs' APAC Director's Cut Conviction List, highlighting a positive outlook for the company due to expected strong patient growth and market share expansion. Meanwhile, Citi upgraded ResMed's stock rating to Buy, increasing the price target to AUD44.00, citing strong EPS growth and free cash flow generation. Conversely, Stifel adjusted its price target to $240 from $250, maintaining a Hold rating due to concerns about the CPAP market and the increasing use of GLP-1 drugs. These developments reflect a mixed but generally optimistic view of ResMed's financial and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.